6-(3-Chloropropoxy)-7-methoxyquinazoline | 1494468-60-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 6-(3-Chloropropoxy)-7-methoxyquinazoline
• CAS: 1494468-60-8
• 化学式: C₁₂H₁₃ClN₂O₂
• 分子量: 252.7
• InChiKey: LXNJLJMMGYKESH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  17
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  44.2
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  6-(3-Chloropropoxy)-7-methoxyquinazoline 在 过氧乙酸 、 硫酸 作用下， 以 乙醇 为溶剂， 反应 8.0h， 以85%的产率得到6-(3-chloropropoxy)-7-methoxyquinazolin-4-ol
  参考文献：
  名称：

  Facile and Efficient Oxidation of Quinazolines into Quinazolin-4(3H)-ones by Peracetic Acid

  摘要：

  A new approach to synthesize quinazoline-4(3H)-ones was achieved by oxidation of quinazolines using peracetic acid, which possesses some advantages of economic reagents, simplified operation, high efficiency, and environmental friendliness. Application of this method allowed us to synthesize a series of quinazolin-4(3H)-ones with different substituents at 6 and 7 positions in good to excellent yields, including the key intermediates of tyrosine kinase inhibitors such as PD153035, Erlotinib, and Gefitinib. [Supplementary materials are available for this article. Go to the publisher's online edition of Synthetic Communications (R) for the following free supplemental resource(s): Full experimental and spectral details.]

  DOI：

  10.1080/00397911.2013.805230
• 作为产物：
  描述：

  5-苄氧基-4-甲氧基-2-硝基苯甲醛 在 盐酸 、 palladium on activated charcoal 、 氢气 、 铁粉 、 potassium carbonate 作用下， 以 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 生成 6-(3-Chloropropoxy)-7-methoxyquinazoline
  参考文献：
  名称：

  Facile and Efficient Oxidation of Quinazolines into Quinazolin-4(3H)-ones by Peracetic Acid

  摘要：

  A new approach to synthesize quinazoline-4(3H)-ones was achieved by oxidation of quinazolines using peracetic acid, which possesses some advantages of economic reagents, simplified operation, high efficiency, and environmental friendliness. Application of this method allowed us to synthesize a series of quinazolin-4(3H)-ones with different substituents at 6 and 7 positions in good to excellent yields, including the key intermediates of tyrosine kinase inhibitors such as PD153035, Erlotinib, and Gefitinib. [Supplementary materials are available for this article. Go to the publisher's online edition of Synthetic Communications (R) for the following free supplemental resource(s): Full experimental and spectral details.]

  DOI：

  10.1080/00397911.2013.805230

文献信息

• [EN] QUINAZOLINE DERIVATIVES AS SRC TYROSINE KINASE INHIBITORS<br/>[FR] DERIVES DE QUINAZOLINE UTILISES COMME INHIBITEURS DE SRC TYROSINE KINASE
  申请人：ASTRAZENECA AB

  公开号：WO2004041829A1

  公开（公告）日：2004-05-21

  The invention concerns quinazoline derivatives of Formula (I): (A chemical formula should be inserted here - please see paper copy enclosed herewith) wherein Z is an O, S, SO, SO2, N(R2) or C(R2)2 group wherein each R2 group is hydrogen or (1-8C) alkyl, m is 0, 1, 2 or 3, each R1 group is selected from halogeno, (1-8C) alkyl, (1-6C) alkoxy and any of the other meanings defined in the description, n is 0, 1, 2 or 3, and each R3 group is selected from halogeno, (1-8C) alkyl, (1-6C) alkoxy and any of the other meanings defined in the description, or pharmaceutically-acceptable salts thereof, processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an anti-invasive agent in the containment and/or treatment of solid tumour disease.

  该发明涉及式（I）的喹唑啉衍生物：其中Z是O、S、SO、SO2、N（R2）或C（R2）2基团，其中每个R2基团是氢或（1-8C）烷基，m为0、1、2或3，每个R1基团选自卤代烷基、（1-8C）烷基、（1-6C）烷氧基和描述中定义的其他含义，n为0、1、2或3，每个R3基团选自卤代烷基、（1-8C）烷基、（1-6C）烷氧基和描述中定义的其他含义，或其药用盐，其制备方法，含有它们的药物组合物以及它们在制备用作抗侵袭剂的药物中的使用，用于抑制和/或治疗实体肿瘤疾病。
• EP1562955A1
  申请人：——

  公开号：EP1562955A1

  公开（公告）日：2005-08-17
• THERAPEUTIC AGENTS COMPRISING AN ANTI-ANGIOGENIC AGENT IN COMBINATION WITH AN SRC-INHIBITOR AND THEIR THERAPEUTIC USE
  申请人：AstraZeneca AB

  公开号：EP1620104A1

  公开（公告）日：2006-02-01
• [EN] THERAPEUTIC AGENTS COMPRISING AN ANTI-ANGIOGENIC AGENT IN COMBINATION WITH AN SRC-INHIBITOR AND THEIR THERAPEUTIC USE<br/>[FR] AGENTS THERAPEUTIQUES CONTENANT UN AGENT ANTI-ANGIOGENIQUE ASSOCIE A UN INHIBITEUR DE SRC, ET LEUR UTILISATION THERAPEUTIQUE
  申请人：ASTRAZENECA AB

  公开号：WO2004098604A1

  公开（公告）日：2004-11-18

  The invention relates to the use of an anti-angiogenic agent in combination with an inhibitor of the Src family of non-receptor tyrosine kinases in the manufacture of a medicament for use in the substantially normotensive treatment in a warm-blooded mammal such as a human being of a disease state associated with angiogenesis, the Src kinase inhibitor being administered in an amount effective to counteract substantially the hypertension induced by the anti-angiogenic agent.